secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001437749-23-031425
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q3 net loss $10.6M; advances cardiac ablation devices toward 510(k) and first-in-human
--------------------------------------------------------------------------------

- GAAP net loss of $10.6M for Q3 2023 vs $18.0M in Q3 2022; non-GAAP net loss $8.5M vs $16.8M.
- Cash and cash equivalents $50.4M as of Sept 30, 2023 vs $69.2M a year ago; Q3 cash burn $8.7M.
- Plan to file 510(k) for cardiac ablation surgical clamp and initiate first-in-human catheter procedure between Dec 2023 and Q1 2024.
- Appointed Dr. Niv Ad as Chief Science Officer, Cardiac Surgery to lead clinical strategy.
- Completed treatment of 21 subjects in thyroid clinical feasibility study; started additional group Nov 7, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/0001437749-23-031425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/plse20231108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer